Belimumab ameliorates symptoms and disease activity in patients with dermatomyositis and juvenile dermatomyositis refractory to standard therapy: A retrospective observational study-Reference-Cited by-同舟云学术

Belimumab ameliorates symptoms and disease activity in patients with dermatomyositis and juvenile dermatomyositis refractory to standard therapy: A retrospective observational study

Published:2024-09 Issue:3 Volume:91 Page:524-527
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Liu Yu,Li Yongzhen,Shen Tian,Zhang Huiming,Luo Shuangyan,Zhang Qing,Dang Xiqiang,Li Xiaoyan,Long Hai^ORCID

Funder

National Key Research and Development Program of China Stem Cell and Translational Research

Hunan Provincial Natural Science Foundation

Changsha Science and Technology Bureau

Hunan Provincial Science and Technology Department

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference5 articles.

1. Elevated serum B-cell activating factor levels in patients with dermatomyositis: association with interstitial lung disease;Matsushita;J Dermatol,2019

2. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial;Oddis;Arthritis Rheum,2013

3. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab;Aggarwal;Rheumatology (Oxford),2017

4. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America;Spencer;Pediatr Rheumatol Online J,2017

5. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study;Grøn;Rheumatology (Oxford),2020